Extraintestinal manifestations of inflammatory bowel disease

被引:69
|
作者
Williams H. [1 ]
Walker D. [1 ]
Orchard T.R. [1 ]
机构
[1] Imperial College London, St. Mary's Hospital, GI Unit, London W2 1NY, Praed Street
关键词
Ulcerative Colitis; Ankylose Spondylitis; Primary Sclerosing Cholangitis; Mesalazine; Pyoderma Gangrenosum;
D O I
10.1007/s11894-008-0108-6
中图分类号
学科分类号
摘要
The idiopathic inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, may be complicated by extraintestinal manifestations (EIMs) in up to 40% of patients. Reports suggest that almost every organ system may be affected. The EIMs are a significant cause of morbidity and may be particularly distressing for the patient. Recent attempts have been made to define the phenotype of IBD in patients of different ethnicities. These studies have highlighted potential racial variations in the prevalence of specific EIMs, findings that are perhaps not surprising given the influence of genetic factors in their pathogenesis. Certain EIMs are related to the activity of the bowel disease, and their management often involves careful monitoring while the IBD is brought under control. Other EIMs, however, typically run a course independent of the IBD activity, and specific, targeted treatments may be required, even including biologic agents such as infliximab. © Springer Science+Business Media, LLC 2008.
引用
收藏
页码:597 / 605
页数:8
相关论文
共 50 条
  • [21] Extraintestinal Manifestations Associated with Inflammatory Bowel Disease
    Brown, Shaun R.
    Coviello, Lisa C.
    SURGICAL CLINICS OF NORTH AMERICA, 2015, 95 (06) : 1245 - +
  • [22] Characterisation of Extraintestinal Manifestations in Inflammatory Bowel Disease, and Chronology of Extraintestinal relative to Intestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort
    Vavricka, Stephan R.
    Rogler, Gerhard
    Gantenbein, Claudine
    Spoerri, Muriel
    Vavricka, Mareike Prinz
    Navarini, Alexander A.
    French, Lars
    Safroneeva, Ekaterina
    Fournier, Nicolas
    Straumann, Alex
    Froehlich, Florian
    Fried, Michael
    Michetti, Pierre
    Schoepfer, Alain M.
    SWISS MEDICAL WEEKLY, 2013, 143 : 14S - 14S
  • [23] Correction to: Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease
    Jurij Hanzel
    Christopher Ma
    Niels Vande Casteele
    Reena Khanna
    Vipul Jairath
    Brian G. Feagan
    Drugs, 2021, 81 : 1697 - 1697
  • [24] Diagnosis and Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease
    Gupta, Abhinav
    Choi, Sarah
    SURGICAL CLINICS OF NORTH AMERICA, 2025, 105 (02) : 385 - 404
  • [25] EXTRAINTESTINAL AND SYSTEMIC MANIFESTATIONS OF INFLAMMATORY BOWEL-DISEASE
    RANKIN, GB
    MEDICAL CLINICS OF NORTH AMERICA, 1990, 74 (01) : 39 - 50
  • [26] Therapies in Inflammatory Bowel Disease Patients with Extraintestinal Manifestations
    Juillerat, Pascal
    Manz, Michael
    Sauter, Bernhard
    Zeitz, Jonas
    Vavricka, Stephan R.
    DIGESTION, 2020, 101 (SUPPL 1) : 83 - 97
  • [27] Extraintestinal Manifestations in Children Diagnosed with Inflammatory Bowel Disease
    Kavcar, Zubeyr
    Civan, Hasret Ayyildiz
    Taskin, Didem Gulcu
    Hatipoglu, Sadik Sami
    MEDICAL BULLETIN OF SISLI ETFAL HOSPITAL, 2023, 57 (01): : 73 - 78
  • [28] EFFECTS OF VEDOLIZUMAB ON EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE
    Dimopoulos, Christina
    Hung, Kenneth
    Proctor, Deborah
    Ruggiero, Eilzabeth
    Al-Bawardy, Badr
    INFLAMMATORY BOWEL DISEASES, 2020, 26 : S19 - S20
  • [29] Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease
    Livne-Margolin, M.
    Ling, D.
    Konyo, S. Attia
    Haj, O.
    Abitbol, C. M.
    Ben-Horin, S.
    Kopylov, U.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I429 - I430
  • [30] Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease
    Siemanowski B.
    Regueiro M.
    Current Treatment Options in Gastroenterology, 2007, 10 (3) : 178 - 184